Company Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.
Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.
The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.
Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| Country | United States |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Dr. Laurent Fischer |
Contact Details
Address: 800 Saginaw Drive Redwood City, California United States | |
| Website | https://www.adverum.com |
Stock Details
| Ticker Symbol | ADVM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501756 |
| CUSIP Number | 00773U108 |
| ISIN Number | US00773U1088 |
| Employer ID | 20-5258327 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laurent Fischer | President, Chief Executive Officer & Director |
| Dena House | Chief People Officer |
| Dr. R. Andrew Ramelmeier Ph.D. | Chief Technology Officer |
| Kishor Peter Soparkar J.D. | Chief Operating Officer |
| Linda M. Rubinstein M.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Carla Fiankan | Senior Vice President of Regulatory Affairs |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer |
| Dr. Romuald Corbau Ph.D. | Chief Scientific Officer |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Development Officer |
| John W. Rakow J.D. | Senior Vice President & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 04, 2024 | 10-Q | Quarterly Report |
| Nov 04, 2024 | 8-K | Current Report |
| Oct 31, 2024 | SCHEDULE 13G | Filing |